Skip to main content

Table 3 Multivariate analysis of overall survival after curative hepatectomy for patients with BCLC 0/A stage HCC

From: Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma

Variable

Comparison

All (n = 820)

CHB (n = 458)

CHC (n = 284)

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Age (years)

>60 vs. ≦ 60

      

Sex

Male vs. Female

      

AFP (ng/mL)

>200 vs. ≦ 200

      

Liver cirrhosis

Yes vs. No

1.644 (1.180–2.290)

0.003

  

1.828 (1.085–3.079)

0.023

Diabetes

Yes vs. No

2.064 (1.478–2.881)

< 0.001

2.633 (1.611–4.303)

< 0.001

1.940 (1.166–3.227)

0.011

Child-Pugh grade

B vs. A

1.915 (1.185–3.096)

0.008

2.223 (1.051–4.702)

0.037

  

Tumor number

Multiple vs. Single

      

Tumor size (cm)

>2 vs. ≦ 2

      

Histology stages

Poor vs. well + moderate

      

Vascular invasion

Yes vs. No

2.339 (1.670–3.276)

< 0.001

2.283 (1.403–3.716)

0.001

3.068 (1.808–5.206)

< 0.001

Statin

Yes vs. No

      

NSAIDs

Yes vs. No

      

Aspirin

Yes vs. No

      

Metformin

Yes vs. No

      

Antiviral therapy

Yes vs. No

0.350 (0.241–0.509)

< 0.001

    

NA therapy

Yes vs. No

  

0.452 (0.277–0.740)

0.002

  

HCV therapy

Yes vs. No

    

0.239 (0.129–0.445)

< 0.001

  1. NSAIDs Nonsteroidal anti-inflammatory drugs, NA therapy Nucleos(t)ide analogues
  2. HCV therapy included interferon and direct-acting antiviral medications